MagnetisMM-6
MAGNETISMM-6: AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE OR ELRANATAMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Arms / Cohorts
Experimental:Part 1, Dose Level 1: Elranatamab + Daratumumab + Lenalidomide
Not yet accepting
Experimental:Part 1, Multiple Dose Levels: Elranatamab + Daratumumab + Lenalidomide
Not yet accepting
Experimental:Part 2 Randomized Arm A: Elranatamab + Daratumumab + Lenalidomide
Not yet accepting
Active Comparator:Part 2 Randomized Arm B: Daratumumab + Lenalidomide + Dexamethasone
Not yet accepting
Experimental:Part 1: Elranatamab + Lenalidomide
Not yet accepting
Experimental:Part 2: Randomized Arm A: Elranatamab + Lenalidomide
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.